WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
I have the largest penis in Britain
James Corden appears in good spirits as he arrives with glamorous wife Julia Carey at the pre
Merlier wins Giro Stage 3 after Pogacar fires up finale and stays in the lead
California congressman urges closer consultation with tribes on offshore wind
Trump's strategist push AI to help conservatives, all you need to know
What we learned from local votes ahead of looming UK general election
Danish King Frederik and his Australian
Ricky Stenhouse punching Kyle Busch could lead to suspension
Ship that caused Baltimore bridge collapse has been refloated
NBC will stick with dual announcers and analysts for the US Open